Valneva SE (VLA.PA)
EUR 1.83
(2.93%)
EUR 1.83
(2.93%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -101.42 Million EUR | 29.21% |
| 2022 | -143.27 Million EUR | -95.14% |
| 2021 | -73.42 Million EUR | -14.03% |
| 2020 | -64.39 Million EUR | -3592.26% |
| 2019 | -1.74 Million EUR | -153.43% |
| 2018 | 3.26 Million EUR | 128.43% |
| 2017 | -11.48 Million EUR | 76.66% |
| 2016 | -49.18 Million EUR | -138.56% |
| 2015 | -20.61 Million EUR | 21.52% |
| 2014 | -26.27 Million EUR | -8.97% |
| 2013 | -24.11 Million EUR | -62.46% |
| 2012 | -14.84 Million EUR | -235.85% |
| 2011 | -4.41 Million EUR | 44.5% |
| 2010 | -7.96 Million EUR | -29.59% |
| 2009 | -6.14 Million EUR | -157.18% |
| 2008 | -2.38 Million EUR | 28.94% |
| 2007 | -3.36 Million EUR | -1283.54% |
| 2006 | -243 Thousand EUR | 80.08% |
| 2005 | -1.22 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -24.93 Million EUR | -142.32% |
| 2024 Q1 | 58.9 Million EUR | 283.19% |
| 2023 Q2 | -16.91 Million EUR | 6.66% |
| 2023 Q4 | -32.15 Million EUR | 6.04% |
| 2023 Q3 | -34.22 Million EUR | -102.29% |
| 2023 FY | -101.42 Million EUR | 29.21% |
| 2023 Q1 | -18.12 Million EUR | 58.99% |
| 2022 Q4 | -44.2 Million EUR | -161.04% |
| 2022 Q1 | -26.04 Million EUR | -115.1% |
| 2022 FY | -143.27 Million EUR | -95.14% |
| 2022 Q3 | 72.41 Million EUR | 149.79% |
| 2022 Q2 | -145.45 Million EUR | -458.55% |
| 2021 Q2 | -58.69 Million EUR | -111.89% |
| 2021 Q3 | -159.53 Million EUR | -171.79% |
| 2021 Q4 | 172.5 Million EUR | 208.13% |
| 2021 FY | -73.42 Million EUR | -14.03% |
| 2021 Q1 | -27.7 Million EUR | -1245.41% |
| 2020 Q4 | -2.05 Million EUR | 94.39% |
| 2020 Q3 | -36.69 Million EUR | -50.33% |
| 2020 Q2 | -24.41 Million EUR | -1886.17% |
| 2020 FY | -64.39 Million EUR | -3592.26% |
| 2020 Q1 | -1.22 Million EUR | -278.12% |
| 2019 Q4 | 690 Thousand EUR | 2190.91% |
| 2019 Q1 | 4.85 Million EUR | -25.53% |
| 2019 Q2 | -7.25 Million EUR | -249.47% |
| 2019 Q3 | -33 Thousand EUR | 99.55% |
| 2019 FY | -1.74 Million EUR | -153.43% |
| 2018 Q1 | 1.45 Million EUR | 139.64% |
| 2018 FY | 3.26 Million EUR | 128.43% |
| 2018 Q4 | 6.51 Million EUR | 312.97% |
| 2018 Q3 | -3.06 Million EUR | -85.23% |
| 2018 Q2 | -1.65 Million EUR | -213.31% |
| 2017 Q1 | -1.65 Million EUR | 39.01% |
| 2017 FY | -11.48 Million EUR | 76.66% |
| 2017 Q4 | -3.67 Million EUR | -6.86% |
| 2017 Q3 | -3.44 Million EUR | -27.25% |
| 2017 Q2 | -2.7 Million EUR | -63.25% |
| 2016 Q1 | -5.03 Million EUR | -546.6% |
| 2016 FY | -49.18 Million EUR | -138.56% |
| 2016 Q4 | -2.71 Million EUR | 61.22% |
| 2016 Q3 | -7 Million EUR | 79.64% |
| 2016 Q2 | -34.42 Million EUR | -583.38% |
| 2015 Q3 | -5.85 Million EUR | 34.78% |
| 2015 Q4 | -779 Thousand EUR | 86.68% |
| 2015 FY | -20.61 Million EUR | 21.52% |
| 2015 Q2 | -8.97 Million EUR | -78.72% |
| 2015 Q1 | -5.01 Million EUR | 56.43% |
| 2014 FY | -26.27 Million EUR | -8.97% |
| 2014 Q4 | -11.52 Million EUR | -348.6% |
| 2014 Q3 | -2.56 Million EUR | 49.36% |
| 2014 Q2 | -5.07 Million EUR | 28.7% |
| 2014 Q1 | -7.11 Million EUR | -17.98% |
| 2013 Q3 | -9.96 Million EUR | -79.12% |
| 2013 FY | -24.11 Million EUR | -62.46% |
| 2013 Q1 | -2.54 Million EUR | 48.09% |
| 2013 Q2 | -5.56 Million EUR | -118.32% |
| 2013 Q4 | -6.02 Million EUR | 39.53% |
| 2012 Q4 | -4.91 Million EUR | -102.22% |
| 2012 Q3 | -2.42 Million EUR | 0.0% |
| 2012 FY | -14.84 Million EUR | -235.85% |
| 2011 FY | -4.41 Million EUR | 44.5% |
| 2010 FY | -7.96 Million EUR | -29.59% |
| 2009 FY | -6.14 Million EUR | -157.18% |
| 2008 FY | -2.38 Million EUR | 28.94% |
| 2007 FY | -3.36 Million EUR | -1283.54% |
| 2006 FY | -243 Thousand EUR | 80.08% |
| 2005 FY | -1.22 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -2783.144% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 31.346% |
| Adocia SA | -21.16 Million EUR | -379.298% |
| Aelis Farma SA | -5.07 Million EUR | -1897.42% |
| Biophytis S.A. | -17.02 Million EUR | -495.73% |
| Advicenne S.A. | -7.03 Million EUR | -1342.597% |
| genOway Société anonyme | 1.56 Million EUR | 6570.44% |
| IntegraGen SA | -171.39 Thousand EUR | -59077.125% |
| Medesis Pharma S.A. | -3.95 Million EUR | -2461.668% |
| Neovacs S.A. | -8.74 Million EUR | -1060.057% |
| NFL Biosciences SA | -3.74 Million EUR | -2608.04% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 128217.066% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -3098.697% |
| Sensorion SA | -22.06 Million EUR | -359.716% |
| Theranexus Société Anonyme | -6.82 Million EUR | -1385.497% |
| TME Pharma N.V. | -6.73 Million EUR | -1405.775% |
| Valbiotis SA | -7.36 Million EUR | -1276.615% |
| TheraVet SA | -1.57 Million EUR | -6357.538% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -398.57% |
| argenx SE | -272.91 Million EUR | 62.835% |
| BioSenic S.A. | -28.77 Million EUR | -252.453% |
| Celyad Oncology SA | -8.44 Million EUR | -1100.627% |
| DBV Technologies S.A. | -67.26 Million EUR | -50.78% |
| Galapagos NV | 211.69 Million EUR | 147.912% |
| Genfit S.A. | -28.89 Million EUR | -251.038% |
| GeNeuro SA | -14.75 Million EUR | -587.328% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -559.486% |
| Innate Pharma S.A. | -7.57 Million EUR | -1239.881% |
| Inventiva S.A. | -110.42 Million EUR | 8.148% |
| MaaT Pharma SA | -19.71 Million EUR | -414.424% |
| MedinCell S.A. | -25.03 Million EUR | -305.1% |
| Nanobiotix S.A. | -39.7 Million EUR | -155.489% |
| Onward Medical N.V. | -36.18 Million EUR | -180.338% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -2925.074% |
| OSE Immunotherapeutics SA | -23 Million EUR | -340.938% |
| Oxurion NV | -18.96 Million EUR | -434.709% |
| Pharming Group N.V. | -9.75 Million EUR | -939.595% |
| Poxel S.A. | -35.09 Million EUR | -189.054% |
| GenSight Biologics S.A. | -26.22 Million EUR | -286.838% |
| Transgene SA | -22.32 Million EUR | -354.268% |
| Financière de Tubize SA | 88.15 Million EUR | 215.062% |
| UCB SA | 343 Million EUR | 129.571% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -257.875% |